Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients Here, we show that circulating insulin-related peptides are elevated in first-onset schizophrenia subjects, with no relative difference in glucose levels. This suggests that hyperinsulinemia may have a role in the development of schizophrenia, and that measurement of these peptides may have utility in diagnosis or stratification of patients before antipsychotic treatment. Moreover, drugs that improve insulin action may represent a novel treatment strategy.
We, along with others, have identified alterations of metabolic biomarkers in schizophrenia patients, which are indicative of perturbations in glucoregulatory pathways. 1 In addition, schizophrenia patients show increased prevalence of impaired glucose tolerance 2 and metabolic syndrome, irrespective of whether they received antipsychotic treatment.
3 Dysregulation of glucose metabolism is normally accompanied by hyperinsulinemia, because of increased secretory demands on pancreatic b-cells to maintain homeostasis. 4 Insulin is the major glucoregulatory hormone produced in b-cell secretory granules by complete proteolytic cleavage of proinsulin. The mature hormone is released into the circulation in response to elevated glucose levels along with approximately 100 other proteins, including residual proinsulin, the conversion intermediates des31,32-proinsulin and des64,65-proinsulin, C-peptide and chromogranin-like molecules. 5 Here we have investigated whether the circulating levels of these major secreted proteins are altered in schizophrenia patients.
Molecular studies of chronic schizophrenia patients can be confounded since routinely used antipsychotic medications have several side effects, such as dysregulated glucose homeostasis. We circumvented this problem by carrying out analyses of serum and plasma samples from first-onset, antipsychotic naïve patients. Recruitment of such patients is challenging, as large clinics diagnose only 20-30 such patients each year and few centers follow standard operating procedures for sample collection. To achieve adequate numbers of well-characterized first-onset patients, we recruited subjects from four independent clinical centers over 2006-2008. Patients were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for schizophrenia and bipolar disorder. Schizophrenia patients were acutely psychotic (Positive and Negative Symptoms Scale total = 87 ± 16; n = 66) and bipolar disorder subjects were euthymic (Young Mania Ratings Scale total = 3.9 ± 4.7, Hamilton Depression scale total = 4.6 ± 5.4; n = 10) at the time of sample collection. Euthymic bipolar disorder patients were chosen, as such subjects often experience cognitive deficits similar to those observed in schizophrenia and this can be a potential means of misdiagnosis. 6 Control subjects (n = 78) were matched for age, gender, BMI and smoking.
Insulin, proinsulin and des31,32-proinsulin were determined through two-site time-resolved fluorescence assays using combinations of monoclonal antibodies that discriminate between the specific forms of the molecule.
7 C-peptide and chromogranin A were measured using commercially available immunoassays. Insulin, proinsulin, des31,32-proinsulin and C-peptide were found to be present at significantly elevated levels in the serum and plasma from schizophrenia patients ( Table 1 ). In addition, chromogranin A was also found at significantly elevated levels.
Glucose levels were unchanged in schizophrenia patients, except for cohort 3, which showed a slight elevation (Table 1) . Therefore, the observed changes in insulin-related molecules occurred against a background of relatively normal glucose levels, suggesting that at least some patients show signs of insulin resistance. Another factor that should be considered is the lack of gender balance in some cohorts. However, covariate analyses showed that this factor had no influence on analyte levels (data not shown). This shows the reproducibility of the findings irrespective of confounding factors such as glycemic status and gender. In contrast, no significant differences were found regarding insulin-related molecules in bipolar disorder patients ( Table 1 ), suggesting that these molecules are not altered in all neuropsychiatric disorders.
Taken together, these findings show that hyperinsulinemia may have a role in the onset of schizophrenia. This has important implications, as elevated insulin levels can have deleterious effects on brain function. 8 In addition, this suggests the possibility that drugs that improve insulin signaling may represent a novel treatment strategy. In this regard, the insulin-related molecules identified here, and potentially other co-secreted insulin-secretory granule proteins, may have utility as biomarkers for patient stratification and for monitoring the responses to existing and novel therapeutic treatment strategies. In a large collaborative study combining three separate whole-genome association studies, the CAC-NA1C gene (rs1006737) was recently found to display a genome-wide significant association with bipolar disorder (BPD). Here, we report for the first time the ND, not determined. Subjects were matched for age (schizophrenia (S)1 (serum) = 25 ± 7 years; S2 (plasma) = 23 ± 4 years; S3 (plasma) = 34 ± 12 years; S4 (serum) = 30±7 years; bipolar disorder (BD) (serum) = 37 ± 11 years) and body mass index (24 ± 5 kg m À2 across all cohorts). Cohorts were comprised (male/female) of the following: S1-controls (cont) = 12/5, schiz = 10/0; S2-cont = 21/0, schiz = 26/0; S3-cont = 6/4, schiz = 7/3; S4-cont = 9/11, schiz = 10/10; BD-cont = 5/5; BD = 5/5. Glucose was determined using the Dimension RXL system (Dade Behring, Dallas, TX, USA) (control levels = 4.6±0.8 mM). Insulin was determined using a two-step time-resolved fluorometric (TRF) assay 9 (control levels = 75.1 ± 58.6 pM). Proinsulin and des31,32-proinsulin were determined using two-site TRF assays 7 (control levels = 4.9±4.4 and 5.9±5.2 pM, respectively). C-peptide was measured using the Immulite system (DPC Diagnostic Products Corp, Los Angeles, CA, USA) (control levels = 1.9±1.3 nM). Chromogranin A was measured using a two-site immunoassay kit (ALPCO Diagnostics, Salem, NH, USA) (control levels = 29.6 ± 21.3 ng ml
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). Fold change (FC) was calculated as the disease:control ratio of analyte levels. Statistical significance (P-value) was determined by two-tailed t-tests. Significant FC values are indicated in bold font.
